Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Comment by slagheapon Jul 15, 2015 2:41am
136 Views
Post# 23924926

RE:started a position here today

RE:started a position here todayThere might be good news with the next quarterly report - around Aug 7 - trying to generate revenue as a reseller but the big one is the phase 3 update expected in October. There appears to be decent institutional interest but they might be the sellers unloading 3m+ per day and the selling appears relentless. If you have read the seekingalpha report the market cap and number of outstanding shares is all over the map - from 95m to 139m so that`s a big question mark. I`m not concerned about it as the big event either way is the phase 3 update. Come December the share price will again be over a dollar but it might need consolidation if the phase 3 goes down the toilet and we don`t want to here for that.
Bullboard Posts